In the syngeneic 4T1 triple-negative breast cancer (TNBC) mouse model, G47Δ-mIL12 treatment significantly reduced the primary tumor burden and metastasis in both early and late stages of tumor development, in a CD8+-dependent fashion [43]. This evidence concerns the gene CD8A and neoplasm.